) A second stymied offering, Mauro Bigonzetti Kazimir’s
Rova T is a novel biomarker specific therapy that targets cancer stem cells and combines a targeted antibody that delivers a cytotoxic agent directly to cancer cells expressing a delta like protein 3 (DLL3). DLL3 is expressed in mor…